Anurag Singh

Dr. Anurag Singh

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2016 in JCI Insight
Verified
Journal Article
Open access
PDF file
NRNikolaus Rieber
Nikolaus Rieber
RGRoel P. Gazendam
Roel P. Gazendam
AFAlexandra F. Freeman
Alexandra F. Freeman
AHAmy P. Hsu
Amy P. Hsu
ACAmanda L. Collar
Amanda L. Collar
MLMichail S. Lionakis
Michail S. Lionakis
Invasive pulmonary aspergillosis is a life-threatening mycosis that only affects patients with immunosuppression, chemotherapy-induced neutropenia, transplantation, or congenital immunodeficiency. We studied the clinical, genetic, histological, and immunological features of 2 unrelated patients without known immunodeficiency who developed extrapulmonary invasive aspergillosis at the ages of 8 and 18. One patient died at age 12 with progressive intra-abdominal aspergillosis. The other patient had presented with intra-abdominal candidiasis at age 9, and developed central nervous system aspergillosis at age 18 and intra-abdominal aspergillosis at age 25. Neither patient developed Aspergillus infection of the lungs. One patient had homozygous M1I CARD9 (caspase recruitment domain family member 9) mutation, while the other had homozygous Q295X CARD9 mutation; both patients lacked CARD9 protein expression. The patients had normal monocyte and Th17 cell numbers in peripheral blood, but their mononuclear cells exhibited impaired production of proinflammatory cytokines upon fungus-specific stimulation. Neutrophil phagocytosis, killing, and oxidative burst against Aspergillus fumigatus were intact, but neither patient accumulated neutrophils in infected tissue despite normal neutrophil numbers in peripheral blood. The neutrophil tissue accumulation defect was not caused by defective neutrophil-intrinsic chemotaxis, indicating that production of neutrophil chemoattractants in extrapulmonary tissue is impaired in CARD9 deficiency. Taken together, our results show that CARD9 deficiency is the first known inherited or acquired condition that predisposes to extrapulmonary Aspergillus infection with sparing of the lungs, associated with impaired neutrophil recruitment to the site of infection.

1 April 2015 in Cell Host & Microbe
Verified
Journal Article
Open access
NRNikolaus Rieber
Nikolaus Rieber
ASAnurag Singh
Anurag Singh
HÖHasan Öz
Hasan Öz
MCMelanie Carevic
Melanie Carevic
MBMaria Bouzani
Maria Bouzani
DHDominik Hartl
Dominik Hartl
Despite continuous contact with fungi, immunocompetent individuals rarely develop pro-inflammatory antifungal immune responses. The underlying tolerogenic mechanisms are incompletely understood. Using both mouse models and human patients, we show that infection with the human pathogenic fungi Aspergillus fumigatus and Candida albicans induces a distinct subset of neutrophilic myeloid-derived suppressor cells (MDSCs), which functionally suppress T and NK cell responses. Mechanistically, pathogenic fungi induce neutrophilic MDSCs through the pattern recognition receptor Dectin-1 and its downstream adaptor protein CARD9. Fungal MDSC induction is further dependent on pathways downstream of Dectin-1 signaling, notably reactive oxygen species (ROS) generation as well as caspase-8 activity and interleukin-1 (IL-1) production. Additionally, exogenous IL-1β induces MDSCs to comparable levels observed during C. albicans infection. Adoptive transfer and survival experiments show that MDSCs are protective during invasive C. albicans infection, but not A. fumigatus infection. These studies define an innate immune mechanism by which pathogenic fungi regulate host defense.

31 March 2016 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
PDF file
MAMichael Abele
Michael Abele
ASAnurag Singh
Anurag Singh
APAndreas Peschel
Andreas Peschel
RMRoman Mehling
Roman Mehling
NRNikolaus Rieber
Nikolaus Rieber
DHDominik Hartl
Dominik Hartl
Myeloid-derived suppressor cells (MDSCs) comprise monocytic and granulocytic innate immune cells with the capability of suppressing T- and NK-cell responses. While the role of MDSCs has been studied in depth in malignant diseases, the understanding of their regulation and function in infectious disease conditions has just begun to evolve. Here we summarize and discuss the current view how MDSCs participate in bacterial infections and how this knowledge could be exploited for potential future therapeutics.

18 October 2018 in EMBO Reports
Verified
Journal Article
Closed access
PDF file
KFKatharina Fuchs
Katharina Fuchs
YGYamel Cardona Gloria
Yamel Cardona Gloria
OWOlaf‐Oliver Wolz
Olaf‐Oliver Wolz
FHFranziska Herster
Franziska Herster
LSLokesh Sharma
Lokesh Sharma
AWAlexander Weber
Alexander Weber

1 December 2017 in Immunology Letters
Verified
Journal Article
Closed access
MBMarlene Ballbach
Marlene Ballbach
ADAngelika Dannert
Angelika Dannert
ASAnurag Singh
Anurag Singh
DSDarina M. Siegmund
Darina M. Siegmund
RHRupert Handgretinger
Rupert Handgretinger
DHDominik Hartl
Dominik Hartl

16 February 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ASAnurag Singh
Anurag Singh
Günalp UzunGünalp Uzun
Günalp Uzun
Tamam BakchoulTamam Bakchoul
Tamam Bakchoul
Immune thrombocytopenia (ITP) is an autoimmune disorder defined by a significantly reduced number of platelets in blood circulation. Due to low levels of platelets, ITP is associated with frequent bruising and bleeding. Current evidence suggests that low platelet counts in ITP are the result of multiple factors, including impaired thrombopoiesis and variations in immune response leading to platelet destruction during pathological conditions. Patient outcomes as well as clinic presentation of the disease have largely been shown to be case-specific, hinting towards ITP rather being a group of clinical conditions sharing common symptoms. The most frequent characteristics include dysfunction in primary haemostasis and loss of immune tolerance towards platelet as well as megakaryocyte antigens. This heterogeneity in patient population and characteristics make it challenging for the clinicians to choose appropriate therapeutic regimen. Therefore, it is vital to understand the pathomechanisms behind the disease and to consider various factors including patient age, platelet count levels, co-morbidities and patient preferences before initiating therapy. This review summarizes recent developments in the pathophysiology of ITP and provides a comprehensive overview of current therapeutic strategies as well as potential future drugs for the management of ITP.